Day and Night Control of COPD and Role of Pharmacotherapy: A Review

References

• LozanoR, NaghaviM, ForemanK, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 55, 2020.
   Google Scholar
• JonesP, MiravitllesM, van der MolenT, KulichK. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697–709. doi:10.2147/COPD.S3267523093901
   PubMed Web of Science ®Google Scholar
• PartridgeMR, KarlssonN, SmallIR, et al. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25:2043–2048. doi:10.1185/0300799090310300619569976
   PubMed Web of Science ®Google Scholar
• BraidoF, BaiardiniI, ScichiloneN, et al. Disability in moderate chronic obstructive pulmonary disease: prevalence, burden and assessment - results from a real-life study. Respiration. 2015;89:100–106. doi:10.1159/00036836525612914
   PubMed Web of Science ®Google Scholar
• AgustiA, HednerJ, MarinJM, BarbéF, CazzolaM, RennardS. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183–194. doi:10.1183/09059180.0000431121881146
   PubMedGoogle Scholar
• TsiligianniI, MettingE, van der MolenT, ChavannesN, KocksJ. Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim Care Respir Med. 2016;21(26):16040. doi:10.1038/npjpcrm.2016.40
   Web of Science ®Google Scholar
• KrönigJ, HildebrandtO, WeissflogA, et al. Long-term recording of night-time respiratory symptoms in patients with stable COPD II-IV. COPD. 2017;14:498–503. doi:10.1080/15412555.2017.133868128715232
   PubMedGoogle Scholar
• KoehlerU, BrandenburgU, WeissflogA, SohrabiK, GroßV.[LEOSound, an innovative procedure for acoustic long-term monitoring of asthma symptoms (wheezing and coughing) in children and adults]. Pneumologie.2014;68:277–281. doi:10.1055/s-0034-1365156. German.24615666
   PubMedGoogle Scholar
• FischerP, GrossV, KroenigJ, et al. Description of nighttime cough epochs in patients with stable COPD GOLD II-IV. Int J Chron Obstruct Pulmon Dis. 2018;13:1071–1078. doi:10.2147/COPD.S15453929662309
   PubMed Web of Science ®Google Scholar
• AkinciB, AslanGK, KiyanE. Sleep quality and quality of life in patients with moderate to very severe chronic obstructive pulmonary disease. Clin Respir J. 2018;12:1739–1746. doi:10.1111/crj.1273829105336
   PubMed Web of Science ®Google Scholar
• LindbergA, BjergA, RönmarkE, LarssonLG, LundbäckB. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking report from the obstructive lung disease in Northern Sweden Studies. Respir Med. 2006;100:264–272.15975774
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, BertleyJC, ChauLK, WebbKA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155:109–115. doi:10.1164/ajrccm.155.1.90012989001298
   PubMed Web of Science ®Google Scholar
• KesslerR, PartridgeMR, MiravitllesM, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–272. doi:10.1183/09031936.0005111021115606
   PubMed Web of Science ®Google Scholar
• DecramerM, RennardS, TroostersT, et al. COPD as a lung disease with systemic consequences–clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5:235–256. doi:10.1080/1541255080223753118671149
   PubMedGoogle Scholar
• ContoliM, SolidoroP, Di MarcoF, et al. Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. Int J Chron Obstruct Pulmon Dis. 2016;11:3043–3050. doi:10.2147/COPD.S12243327980401
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, ElbehairyAF, FaisalA, WebbKA, NederJA, MahlerDA. Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev. 2016;25:333–347. doi:10.1183/16000617.0054-201627581832
   PubMed Web of Science ®Google Scholar
• HanninkJD, van HelvoortHA, DekhuijzenPN, HeijdraYF. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest. 2010;137:1116–1121. doi:10.1378/chest.09-184719952059
   PubMed Web of Science ®Google Scholar
• KatzS, ArishN, RokachA, ZaltzmanY, MarcusE-L. The effect of body position on pulmonary function: a systematic review. BMC Pulm Med. 2018;18(1):159. doi:10.1186/s12890-018-0723-430305051
   PubMed Web of Science ®Google Scholar
• KangW, ClarkAR, TawhaiMH. Gravity outweighs the contribution of structure to passive ventilation-perfusion matching in the supine adult human lung. J Appl Physiol (1985). 2018;124(1):23–33. doi:10.1152/japplphysiol.00791.201629051337
   PubMed Web of Science ®Google Scholar
• PecchiariM, RadovanovicD, SantusP, D’AngeloE. Airway occlusion assessed by single breath N2 test and lung P-V curve in healthy subjects and COPD patients. Respir Physiol Neurobiol. 2016;234:60–68. doi:10.1016/j.resp.2016.09.00627612586
   PubMed Web of Science ®Google Scholar
• PecchiariM, SantusP, RadovanovicD, D’AngeloE. Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N2 test and lung P-V curve. J Appl Physiol. 1985;2017(123):1266–1275.
   Google Scholar
• SantusP, RadovanovicD, MascettiS, et al. Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD. Pharmacol Res. 2018;133:160–169. doi:10.1016/j.phrs.2018.05.01029775687
   PubMed Web of Science ®Google Scholar
• WatzH. Chronic obstructive pulmonary disease: when pulmonologists do something good for the heart. Am J Respir Crit Care Med. 2016;193:703–704. doi:10.1164/rccm.201512-2340ED27035775
   PubMed Web of Science ®Google Scholar
• AtherS, ChanW, BozkurtB, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005. doi:10.1016/j.jacc.2011.11.04022402071
   PubMed Web of Science ®Google Scholar
• SantusP, RadovanovicD, Di MarcoS, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–1923. doi:10.2147/COPD.S9168426392766
   PubMed Web of Science ®Google Scholar
• StoneIS, BarnesNC, JamesWY, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med. 2016;193:717–726. doi:10.1164/rccm.201508-1647OC26550687
   PubMed Web of Science ®Google Scholar
• HohlfeldJM, Vogel-ClaussenJ, BillerH, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–378. doi:10.1016/S2213-2600(18)30054-729477448
   PubMed Web of Science ®Google Scholar
• RadovanovicD, ContoliM, MarcoFD, et al. Functional characteristics of COPD patients across GOLD classifications: results of a multicenter observational study. COPD. 2019;16(3–4):215–226. doi:10.1080/15412555.2019.165976031500459
   PubMedGoogle Scholar
• TabachnikE, MullerNL, BryanAC, LevisonH. Changes in ventilation and chest wall mechanics during sleep in normal adolescents. J Appl Physiol Respir Environ Exerc Physiol. 1981;51(3):557–564. doi:10.1152/jappl.1981.51.3.5577327955
   PubMed Web of Science ®Google Scholar
• MarroneO, SalvaggioA, InsalacoG. Respiratory disorders during sleep in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1:363–372. doi:10.2147/copd.2006.1.4.36318044093
   PubMedGoogle Scholar
• O’DonoghueFJ, CatchesidePG, EllisEE, et al. Australian trial of noninvasive ventilation in chronic airflow limitation investigators. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors. Eur Respir J. 2003;21:977–984.12797491
   PubMed Web of Science ®Google Scholar
• CatterallJR, RhindGB, StewartIC, WhyteKF, ShapiroCM, DouglasNJ. Effect of sleep deprivation on overnight bronchoconstriction in nocturnal asthma. Thorax. 1986;41:676–680. doi:10.1136/thx.41.9.6763787554
   PubMed Web of Science ®Google Scholar
• MorrisonJF, PearsonSB. The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma. Br J Clin Pharmacol. 1989;28:545–549. doi:10.1111/j.1365-2125.1989.tb03540.x2531606
   PubMed Web of Science ®Google Scholar
• DurringtonHJ, FarrowSN, LoudonAS, RayDW. The circadian clock and asthma. Thorax. 2014;69:90–92. doi:10.1136/thoraxjnl-2013-20348223704227
   PubMed Web of Science ®Google Scholar
• MartinRJ. Small airway and alveolar tissue changes in nocturnal asthma. Am J Respir Crit Care Med. 1998;157(5 Pt 2):S188–S190. doi:10.1164/ajrccm.157.5.rsaa-49606318
   PubMed Web of Science ®Google Scholar
• BatemanED, FergusonGT, BarnesN, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484–1494. doi:10.1183/09031936.0020021223722616
   PubMed Web of Science ®Google Scholar
• LeeJS, HuhJW, ChaeEJ, et al. Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease. Clin Physiol Funct Imaging. 2012;32:12–18. doi:10.1111/j.1475-097X.2011.01046.x22152074
   PubMed Web of Science ®Google Scholar
• IqbalA, BarnesNC, BrooksJ. Is blood eosinophil count a predictor of response to bronchodilators in chronic obstructive pulmonary disease? Results from post hoc subgroup analyses. Clin Drug Investig. 2015;35:685–688. doi:10.1007/s40261-015-0322-6
   PubMed Web of Science ®Google Scholar
• van den BemtL, SchermerT, SmeeleI, et al. Monitoring of patients with COPD: a review of current guidelines’ recommendations. Respir Med. 2008;102:633–641. doi:10.1016/j.rmed.2007.12.01418242067
   PubMed Web of Science ®Google Scholar
• AgustiA. The path to personalised medicine in COPD. Thorax. 2014;69(9):857–864. doi:10.1136/thoraxjnl-2014-20550724781218
   PubMed Web of Science ®Google Scholar
• PartridgeMR, MiravitllesM, StåhlE, KarlssonN, SvenssonK, WelteT. Development and validation of the capacity of daily living during the morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010;36:96–104. doi:10.1183/09031936.0012370919897551
   PubMed Web of Science ®Google Scholar
• JonesPW, HardingG, BerryP, WiklundI, ChenWH, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• JonesPW, LeidyNK, HareendranA, LamarcaR, ChuecosF, Garcia GilE. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016;17:61. doi:10.1186/s12931-016-0372-127215749
   PubMed Web of Science ®Google Scholar
• LeidyNK, MurrayLT, MonzBU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15:124. doi:10.1186/s12931-014-0124-z25287629
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJ, MarzoM, CatalánP, MirallesC, AlcazarB, MiravitllesM. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719–3731. doi:10.2147/COPD.S17814930532528
   PubMed Web of Science ®Google Scholar
• BraidoF, BaiardiniI, MolinengoG, et al. Choose your outcomes: from the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. Eur J Intern Med. 2016;34:85–88. doi:10.1016/j.ejim.2016.05.03027324818
   PubMed Web of Science ®Google Scholar
• NunesDM, MotaRM, de Pontes NetoOL, PereiraED, de BruinVM, de BruinPF. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009;187:159–163. doi:10.1007/s00408-009-9147-519399553
   PubMed Web of Science ®Google Scholar
• OmachiTA, BlancPD, ClamanDM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476–483. doi:10.1016/j.sleep.2011.12.00722429651
   PubMed Web of Science ®Google Scholar
• LangeP, MarottJL, VestboJ, NordestgaardBG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590–1598. doi:10.1183/09031936.0019671324488571
   PubMed Web of Science ®Google Scholar
• KwonJS, WolfeLF, LuBS, KalhanR. Hyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apnea. COPD. 2009;6:441–445. doi:10.3109/1541255090343300019938967
   PubMedGoogle Scholar
• BasileM, BaiamonteP, MazzucaE, et al. Sleep disturbances in COPD are associated with heterogeneity of airway obstruction. COPD. 2018;15:350–354. doi:10.1080/15412555.2018.150401530188194
   PubMedGoogle Scholar
• PokrzywinskiRF, MeadsDM, McKennaSP, GlendenningGA, RevickiDA. Development and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS). Health Qual Life Outcomes. 2009;7:98. doi:10.1186/1477-7525-7-9819968881
   PubMed Web of Science ®Google Scholar
• CalverleyPM, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• CanonicaGW, BlasiF, ScichiloneN, et al.; STORICO study group. Characterization of circadian COPD symptoms by phenotype: methodology of the STORICO observational study. Eur J Intern Med. 2017;43:62–68.28576398
   PubMed Web of Science ®Google Scholar
• BelliaV, CatalanoF, ScichiloneN, et al. Sleep disorders in the elderly with and without chronic airflow obstruction: the SARA study. Sleep. 2003;26:318–323. doi:10.1093/sleep/26.3.31812749552
   PubMed Web of Science ®Google Scholar
• CazzolaM, PageCP, CalzettaL, MateraMG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.22611179
   PubMed Web of Science ®Google Scholar
• TashkinDP, FabbriLM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149. doi:10.1186/1465-9921-11-14921034447
   PubMed Web of Science ®Google Scholar
• CalzettaL, MateraMG, CazzolaM. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168–173. doi:10.1016/j.ejphar.2015.05.02025981302
   PubMed Web of Science ®Google Scholar
• CazzolaM, CalzettaL, SegretiA, FaccioloF, RoglianiP, MateraMG. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2015;12:175–181. doi:10.3109/15412555.2014.92217225222881
   PubMedGoogle Scholar
• CrisafulliE, PisiR, AielloM, et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017;93:32–41. doi:10.1159/00045247927852080
   PubMed Web of Science ®Google Scholar
• WesslerI, KirkpatrickCJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol. 2008;154:1558–1571. doi:10.1038/bjp.2008.18518500366
   PubMed Web of Science ®Google Scholar
• ProfitaM, BonannoA, MontalbanoAM, et al. β₂ long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta. 2012;1822:1079–1089. doi:10.1016/j.bbadis.2012.03.00222440430
   PubMed Web of Science ®Google Scholar
• CazzolaM, CalzettaL, PuxedduE, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17:70. doi:10.1186/s12931-016-0386-827296533
   PubMed Web of Science ®Google Scholar
• SullivanP, BekirS, JaffarZ, PageC, JefferyP, CostelloJ. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet. 1994;343(8904):1006–1008. doi:10.1016/S0140-6736(94)90127-97909049
   PubMed Web of Science ®Google Scholar
• NicholsonCD, ShahidM. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes–their potential utility in the therapy of asthma. Pulm Pharmacol. 1994;7(1):1–17. doi:10.1006/pulp.1994.10018003849
   PubMedGoogle Scholar
• ItoK, LimS, CaramoriG, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002;99(13):8921–8926. doi:10.1073/pnas.13255689912070353
   PubMed Web of Science ®Google Scholar
• LimS, JatakanonA, GordonD, MacdonaldC, ChungKF, BarnesPJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax. 2000;55(10):837–841. doi:10.1136/thorax.55.10.83710992535
   PubMed Web of Science ®Google Scholar
• UkenaD, HarnestU, SakalauskasR, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997;10(12):2754–2760. doi:10.1183/09031936.97.101227549493656
   PubMed Web of Science ®Google Scholar
• SlackRJ, BarrettVJ, MorrisonVS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218–230. doi:10.1124/jpet.112.19848123131596
   PubMed Web of Science ®Google Scholar
• CalzettaL, RoglianiP, FaccioloF, RendinaE, CazzolaM, MateraMG. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017;812:147–154. doi:10.1016/j.ejphar.2017.07.02628716723
   PubMed Web of Science ®Google Scholar
• NalineE, Grassin DelyleS, SalvatorH, et al. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther. 2018;49:46–53. doi:10.1016/j.pupt.2018.01.00329337266
   PubMed Web of Science ®Google Scholar
• PascoeS, LocantoreN, DransfieldMT, BarnesNC, PavordID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442. doi:10.1016/S2213-2600(15)00106-X25878028
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al.; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.29668352
   PubMed Web of Science ®Google Scholar
• MagnussenH, DisseB, Rodriguez-RoisinR, et al.; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294.25196117
   PubMed Web of Science ®Google Scholar
• CalzettaL, MateraMG, BraidoF, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148–158. doi:10.1016/j.pupt.2017.06.00228606478
   PubMed Web of Science ®Google Scholar
• ReillyJJ. Stepping down therapy in COPD. N Engl J Med. 2014;371:1340–1341. doi:10.1056/NEJMe140921925196116
   PubMed Web of Science ®Google Scholar
• ChapmanKR, HurstJR, FrentSM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198:329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• NanniniLJ, LassersonTJ, PooleP. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
   PubMed Web of Science ®Google Scholar
• NanniniLJ, CatesCJ, LassersonTJ, PooleP. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826.
   PubMed Web of Science ®Google Scholar
• NanniniLJ, PooleP, MilanSJ, HolmesR, NormansellR. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD003794.
   PubMed Web of Science ®Google Scholar
• ManoharanA, ShortPM, AndersonWJ, LipworthBJ. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung. 2014;192:649–652. doi:10.1007/s00408-014-9611-824952426
   PubMed Web of Science ®Google Scholar
• VestboJ, FabbriL, PapiA, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52.
   Web of Science ®Google Scholar
• SinghD, FabbriLM, VezzoliS, PetruzzelliS, PapiA. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019;28(14):531–546. doi:10.2147/COPD.S196383
   Web of Science ®Google Scholar
• JenR, RennardSI, SinDD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:587–595. doi:10.2147/COPD.S3276523055709
   PubMed Web of Science ®Google Scholar
• KunzLI, StrebusJ, BudulacSE, et al; GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One. 2013;8(5):e63430.23667615
   PubMed Web of Science ®Google Scholar
• TantucciC, ModinaD. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/COPD.S2748022371650
   PubMed Web of Science ®Google Scholar
• SinghD, FabbriLM, CorradiM, et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur Respir J. 2019;53.
   Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-830232048
   PubMed Web of Science ®Google Scholar
• CazzolaM, RoglianiP, CalzettaL, MateraMG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586. doi:10.1183/13993003.01586-201830309975
   PubMed Web of Science ®Google Scholar
• KellyHW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009;43(3):519–527. doi:10.1345/aph.1L54619261959
   PubMed Web of Science ®Google Scholar
• WoodcockA, BatemanED, BusseWW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res. 2011;12:132. doi:10.1186/1465-9921-12-13221977941
   PubMed Web of Science ®Google Scholar
• WoodcockA, BleeckerER, BusseWW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12:160. doi:10.1186/1465-9921-12-16022188590
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma; 2019 Available from: https://ginasthma.org/. Accessed 55, 2020.
   Google Scholar
• BeierJ, MrozR, KirstenAM, ChuecosF, GilEG. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study. Int J Chron Obstruct Pulmon Dis. 2017;12:1731–1740. doi:10.2147/COPD.S12172328652725
   PubMed Web of Science ®Google Scholar
• CalverleyPM, RennardSI, Clerisme-BeatyE, MetzdorfN, ZubekVB, ZuWallackR. Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. Respir Res. 2016;17(1):27. doi:10.1186/s12931-016-0340-926971242
   PubMed Web of Science ®Google Scholar
• ArievichH, OverendT, RenardD, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012;12:74. doi:10.1186/1471-2466-12-7423217058
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, LeeA, TowseL, van NoordJ, WitekTJ, KelsenS. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58:855–860. doi:10.1136/thorax.58.10.85514514937
   PubMed Web of Science ®Google Scholar
• SantusP, PiccioloS, ProiettoA, et al. Doctor-patient relationship: a resource to improve respiratory diseases management. Eur J Intern Med. 2012;23:442–446. doi:10.1016/j.ejim.2012.04.00422726373
   PubMed Web of Science ®Google Scholar
• OsterbergL, BlaschkeT. Adherence to medication. N Engl J Med. 2005;353:487–497. doi:10.1056/NEJMra05010016079372
   PubMed Web of Science ®Google Scholar
• BelleudiV, Di MartinoM, CasciniS, et al. OUTPUL Study Group. The impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approach. Pharmacoepidemiol Drug Saf. 2016;25:1295–1304. doi:10.1002/pds.405927396695
   PubMed Web of Science ®Google Scholar
• GeorgeJ, KongDC, ThomanR, StewartK. Factors associated with medication nonadherence in patients with COPD. Chest. 2005;128:3198–3204. doi:10.1378/chest.128.5.319816304262
   PubMed Web of Science ®Google Scholar
• JungE, PickardAS, SalmonJW, BartleB, LeeTA. Medication adherence and persistence in the last year of life in COPD patients. Respir Med. 2009;103:525–534. doi:10.1016/j.rmed.2008.11.00419136240
   PubMed Web of Science ®Google Scholar
• KrigsmanK, NilssonJL, RingL. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf. 2007;16:441–448. doi:10.1002/pds.132117006959
   PubMed Web of Science ®Google Scholar
• RoglianiP, OraJ, PuxedduE, MateraMG, CazzolaM. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117–123. doi:10.1016/j.rmed.2017.06.00728732818
   PubMed Web of Science ®Google Scholar
• BourbeauJ, BartlettSJ. Patient adherence in COPD. Thorax. 2008;63(9):831–838. doi:10.1136/thx.2007.08604118728206
   PubMed Web of Science ®Google Scholar
• VetranoDL, BianchiniE, OnderG, et al. Poor adherence to chronic obstructive pulmonary disease medications in primary care: role of age, disease burden and polypharmacy. Geriatr Gerontol Int. 2017;17(12):2500–2506. doi:10.1111/ggi.1311528656664
   PubMed Web of Science ®Google Scholar
• MuellerS, WilkeT, BechtelB, PunekarYS, MitznerK, VirchowJC. Non-persistence and non-adherence to long-acting COPD medication therapy: a retrospective cohort study based on a large German claims dataset. Respir Med. 2017;122:1–11. doi:10.1016/j.rmed.2016.11.00827993284
   PubMed Web of Science ®Google Scholar
• MelaniAS, BonaviaM, CilentiV, et al.; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.21367593
   PubMed Web of Science ®Google Scholar
• ViswanathanM, GolinCE, JonesCD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157:785–795. doi:10.7326/0003-4819-157-11-201212040-0053822964778
   PubMed Web of Science ®Google Scholar
• GuestJF, DavieAM, RuizFJ, GreenerMJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005;14:88–98. doi:10.1016/j.pcrj.2005.01.00216701704
   PubMedGoogle Scholar
• PriceD, RobertsonA, BullenK, RandC, HorneR, StaudingerH. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1. doi:10.1186/1471-2466-10-120051135
   PubMed Web of Science ®Google Scholar
• StormsW. Clinical trials: are these your patients? J Allergy Clin Immunol. 2003;112(5):S107–11. doi:10.1016/j.jaci.2003.09.01914586395
   PubMedGoogle Scholar
• JonassonG, CarlsenKH, MowinckelP. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83:330–333. doi:10.1136/adc.83.4.33010999870
   PubMed Web of Science ®Google Scholar
• IzquierdoJL, ParederoJM, PiedraR. Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;10(11):289–293. doi:10.2147/COPD.S96948
   Web of Science ®Google Scholar
• ToyEL, BeaulieuNU, McHaleJM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.00620880687
   PubMed Web of Science ®Google Scholar
• PriceD, LeeAJ, SimsEJ, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J. 2013;22(2):161–168. doi:10.4104/pcrj.2013.0001723460035
   PubMedGoogle Scholar
• SmithMC, WrobelJP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD.S4962125210449
   PubMed Web of Science ®Google Scholar
• BattagliaS, BasileM, ScichiloneN, BelliaV. Prevalence of Co-morbidities and Severity of COPD. COPD. 2015;12:390–394. doi:10.3109/15412555.2014.97473425415502
   PubMedGoogle Scholar
• ScichiloneN, ContinoA, FiglioliGB, PaglinoG, BelliaV. Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Patient Prefer Adherence. 2010;4:17–23. doi:10.2147/PPA.S562720165595
   PubMed Web of Science ®Google Scholar
• ScichiloneN, BenfanteA, BocchinoM, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–67. doi:10.1016/j.pupt.2015.02.00625724817
   PubMed Web of Science ®Google Scholar
• WieshammerS, DreyhauptJ. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75:18–25. doi:10.1159/00010937417911976
   PubMed Web of Science ®Google Scholar
• GiraudV, RocheN. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19:246–251. doi:10.1183/09031936.02.0021840211866004
   PubMed Web of Science ®Google Scholar
• van der PalenJ, KleinJJ, van HerwaardenCL, ZielhuisGA, SeydelER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14:1034–1103. doi:10.1183/09031936.99.1451034910596686
   PubMed Web of Science ®Google Scholar
• DolovichMB, AhrensRC, HessDR, et al.; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371.15654001
   PubMed Web of Science ®Google Scholar
• LavoriniF, PedersenS, UsmaniOS; Aerosol Drug Management Improvement Team (ADMIT). Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest. 2017;151(6):1345–1355.27522955
   PubMed Web of Science ®Google Scholar
• HanMK, QuibreraPM, CarrettaEE, et al.; SPIROMICS investigators. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626.28668356
   PubMed Web of Science ®Google Scholar
• HoggJC, ChuFS, TanWC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007;176(5):454–459. doi:10.1164/rccm.200612-1772OC17556723
   PubMed Web of Science ®Google Scholar